SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Oracle Corp. engages in the provision of products and services that address aspects of corporate information technology environments, including applications and infrastructure technologies. It operates through the following business segments: Cloud and License, Hardware, and Services. The Cloud and License segment markets, sells, and delivers enterprise applications and infrastructure technologies through cloud and on-premise deployment models including cloud services and license support offerings. The Hardware segment provides infrastructure technologies including Oracle Engineered Systems, servers, storage, industry-specific hardware, operating systems, virtualization, management, and other hardware-related software. The Services segment offers consulting, advanced support, and education services. The company was founded by Lawrence Joseph Ellison, Robert Nimrod Miner, and Edward A. Oates on June 16, 1977 and is headquartered in Austin, TX.

Oracle Corp.

Oracles sharp selloff and reversal of gains after an upbeat investor-day outlook dominate discussion, with traders questioning whether its AI backlog can justify heavy spending and debt before cash flow improves. Some see the funding and cash-flow plan as reassurance, while others blame broader tech weakness and reaction to Google and Amazon results for renewed selling.

Palantir Technologies, Inc. engages in the business of building and deploying software platforms that serve as the central operating systems for its customers. It operates through the Commercial and Government segments. The Commercial segment focuses on customers working in non-government industries. The Government segment is involved in providing services to customers that are the United States government and non-United States government agencies. Its platforms are widely used in areas such as defense, intelligence, healthcare, energy, and financial services, supporting data integration, large-scale analytics, and operational decision-making. The company was founded by Alexander Ceadmon Karp, Peter Andreas Thiel, Stephen Cohen, Joseph Lonsdale, and Nathan Dale Gettings in 2003 and is headquartered in Aventura, FL.

Palantir Technologies Inc - Ordinary Shares - Class A

Palantir Technologies Inc

Palantirs upcoming Q3 report is the main focus, with traders debating whether strong results and higher guidance can clear an elevated bar as AI stocks face pressure. Bulls expect continued growth in its AI business, while bears argue that even a beat may not justify the valuation and could prompt further selling.

TG Therapeutics, Inc. engages in the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its product pipeline includes TG-1501, TG-1701, Ublituximab, and Umbralisib. The company was founded by Michael Sean Weiss and Laurence H. Shaw on May 18, 1993 and is headquartered in Morrisville, NC.

TG Therapeutics Inc

TGTXs breakout to a fresh 52-week high has traders focused on the upcoming Q3 results and BRIUMVIs growth, with the subcutaneous BRIUMVI readout also viewed as a potential catalyst. Heavy call activity and high short interest are fueling squeeze and buyout speculation, though the community disagrees on whether the rally reflects positioning around company fundamentals or an unconfirmed deal rumor.

Stellar (XLM) is a cryptocurrency launched in 2014. Stellar has a current supply of 50,001,786,837.39707 with 35,251,440,068.9505 in circulation. The last known price of Stellar is 0.16728777 USD and is down -1.15 over the last 24 hours. It is currently trading on 848 active market(s) with $82,083,533.38 traded over the last 24 hours. More information can be found at https://www.stellar.org.

Stellar Lumens

XLM is drawing attention for persistent selling and weak price action, with traders saying it struggles to hold key levels and underperforms despite institutional-adoption headlines. The debate centers on whether DTCC and real-world-asset tokenization developments will eventually support the token, while skeptics argue that low fees and token economics may limit any price impact; some also allege ongoing SDF selling.

Salesforce, Inc. engages in the design and development of cloud-based enterprise software for customer relationship management. Its solutions include sales force automation, customer service and support, marketing automation, digital commerce, community management, collaboration, industry-specific solutions, and salesforce platform. The firm also provides guidance, support, training, and advisory services. The company was founded by Marc Russell Benioff and Parker Harris in 1999 and is headquartered in San Francisco, CA.

Salesforce Inc

Salesforces planned acquisition of Braze has drawn attention, with traders weighing the strategic boost to its AI-powered marketing and customer-engagement offerings against concerns about the deals price and integration risks. The discussion also reflects broader debate over whether AI will strengthen or disrupt established software platforms.

Pepe (PEPE) is a cryptocurrency launched in 2023and operates on the Ethereum platform. Pepe has a current supply of 413,772,350,098,130.40630647. The last known price of Pepe is 0.00000489 USD and is down -3.02 over the last 24 hours. It is currently trading on 729 active market(s) with $389,285,493.23 traded over the last 24 hours. More information can be found at https://www.pepe.vip/.

Pepe

PEPE is drawing attention for volatile, largely range-bound trading, with traders watching repeated tests of resistance and debating whether rebounds signal a breakout or another short-lived pump. Dip-buying and accumulation calls contrast with concerns about continued declines, pump-and-dump behavior, and moves tracking broader crypto-market weakness.

Amgen, Inc. is a biotechnology company, which engages in the discovery, development, manufacture, and marketing of human therapeutics. The company was founded by William K. Bowes, Jr., Franklin Pitcher Johnson, Jr., George B. Rathmann, and Joseph Rubinfeld on April 8, 1980 and is headquartered in Thousand Oaks, CA.

AMGEN Inc.

Amgens Phase 3 lung-cancer data for IMDELLTRA with AstraZenecas IMFINZI, showing a lower risk of death in extensive-stage small-cell lung cancer, is driving attention. Traders view the result as a promising oncology growth catalyst, alongside discussion of Repathas growth and Amgens upcoming earnings.

Hyperliquid (HYPE) is a cryptocurrency and operates on the Hyperliquid platform. Hyperliquid has a current supply of 950,394,442.10256707 with 253,500,314.85654783 in circulation. The last known price of Hyperliquid is 87.94735104 USD and is down -0.18 over the last 24 hours. It is currently trading on 350 active market(s) with $1,050,863,479.79 traded over the last 24 hours. More information can be found at https://hyperliquid.xyz/.

Hype

Hyperliquids HYPE is drawing attention for its strong rally toward record highs, with traders focused on revenue-funded token buybacks and burns and growing institutional access to its trading platform. Bullish calls about the protocols growth and token demand are tempered by concerns about volatility, pullbacks, and profit-taking.

Liquidia Corp. operates as a holding company which engages through its subsidiary in developing and commercializing biopharmaceutical products and novel products development used in PRINT technology to transform the lives of patients. The company was founded in June 2004 and is headquartered in Morrisville, NC.

Liquidia Corp

Liquidias settlement with United Therapeutics resolved all six lawsuits, keeping Yutrepia available for PAH while giving up the PH-ILD indication and requiring substantial payments. Traders welcomed the reduced legal uncertainty and speculated about a short squeeze, while others focused on the lost market opportunity and financial burden.

Astera Labs, Inc. provides rack-scale AI infrastructure through purpose-built connectivity solutions. The company offers a range of semiconductor-based connectivity solutions designed to address bandwidth, latency, and reliability challenges in AI and cloud data centers. The company was founded by Jitendra Mohan, Casey Morrison, and Sanjay Gajendra in October 2017 and headquartered in San Jose, CA.

Astera Labs Inc.

Astera Labs Inc

Astera Labs is facing a sharp pullback as traders debate its high valuation and broader weakness in AI and semiconductor stocks, with upcoming earnings and guidance viewed as a test of demand for its data-center connectivity products. Some see the decline as a buying opportunity tied to continued AI infrastructure spending, while others expect further downside or a post-earnings selloff.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Cencora Gears Up to Report Q4 Results: How to Play the Stock?

COR's Q4 earnings are likely to benefit from strong specialty pharma demand and MSO growth, but pricing pressures and higher interest costs may weigh on results.

Revvity Gears Up to Post Q3 Earnings: What's in Store for the Stock?

RVTY's Q3 earnings may gain from recovering pharma demand, stronger HCS demand and software growth, despite lingering spending and TB-related headwinds.

STERIS Set to Report Q2 Earnings: What's in the Cards for the Stock?

STE's second-quarter fiscal 2027 earnings may benefit from Healthcare growth, recent acquisitions, easing AST comparisons and continued margin expansion.

BTSG Ahead of Q3 Earnings: Can Growth Offset Ongoing IRA Risks?

BrightSpring gears up for Q3 earnings, with strong Specialty, Infusion and Provider Services growth expected to offset IRA headwinds. Can it beat estimates?

Zimmer Biomet Gears Up to Report Q3 Earnings: What's in the Cards?

ZBH heads into Q3 earnings with growth expected in Hips, S.E.T. and Technology & Data, while Knee sales face ongoing pressure.

Waters Gears Up to Report Q3 Results: How to Play the Stock?

WAT's Q3 results are likely to benefit from strong revenue growth prospects, rising demand and acquisition gains.

NTRA Q3 Earnings on Deck: Will Signatera Volume Growth Drive Results?

Natera's third-quarter 2026 results hinge on Signatera volume growth, regulatory milestones and higher test prices, while expanding Medicare coverage may boost organ health revenues.

Veracyte (VCYT) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

Veracyte (VCYT) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

ACB's Q2 Earnings on Deck: International Medical Cannabis in Focus

Aurora Cannabis heads into Q2 earnings with revenues expected to fall 20.1%, as market exits and reimbursement cuts weigh on results while international medical cannabis markets offer support.

DexCom Gears Up to Report Q3 Results: How to Play the Stock?

DXCM Q3 earnings are likely to benefit from CGM adoption, G7 15 Day uptake and wider reimbursement amid tougher international comparisons.

IDEXX Laboratories, Inc. engages in the development, manufacturing, and distribution of products and services for the animal veterinary, livestock and poultry, dairy, and water testing industries. It operates through the following segments: Companion Animal Group (CAG), Water Quality Products (Water), Livestock, Poultry, and Dairy (LPD), and Other. The CAG segment provides diagnostic and information management-based products and services for the companion animal veterinary industry, including in-clinic diagnostic solutions, outside reference laboratory services, and veterinary software and services. The Water segment offers innovative testing solutions for easy, rapid, and accurate detection and quantification of various microbiological parameters in water. The LPD segment develops diagnostic tests, services, and related instrumentation that are used to manage the health status of livestock and poultry, to improve producer efficiency, and to ensure the quality and safety of milk and food. The Other segment is composed of products for the human point-of-care medical diagnostics market with its out-licensing arrangements. The company was founded by David Evans Shaw on December 19, 1983 and is headquartered in Westbrook, ME.

Idexx Laboratories, Inc.

IDEXX Reports Upbeat Q1 Profit, Upgrades Full-Year Guidance: Retail’s Positive

Equity

Bearish Sentiment

Shares of IDEXX Laboratories, Inc. (IDXX) traded 9% higher on Thursday afternoon after the company <a target="_blank" rel="noopener noreferrer nofollow" href="https://www.idexx.com/files/2025-q1-earnings-release-20250501.pdf">reported</a> upbeat first-quarter profit and raised its annual forecast.The veterinary diagnostics company’s first-quarter (Q1) revenue came in at $998 million, marking an increase of 4% year-on-year (YoY), but below an analyst estimate of $999.52 million, as per Finchat data.Diluted earnings per share came in at $2.96, up from $2.81 in the corresponding period of 2024, and exceeding an estimated $2.84.The company adjusted its full-year revenue guidance to $4.1 billion to $4.21 billion, reflecting the benefits of foreign exchange impacts, up from its previous estimate of $4.06 billion to $4.17 billion.IDEXX also updated its full-year EPS outlook to $11.93 to $12.43, up from previous guidance of $11.74 to $12.24. The new earnings guidance includes a favorable adjustment to a now-concluded litigation matter expense accrual, the company said.The firm also updated its full-year operating margin outlook to 31.1% to 31.6% from 31% to 31.5%, including estimates for the impact of tariffs.The new estimates include tariffs on internationally sourced materials, based on current U.S. pronouncements and forecasts for China’s retaliatory tariffs, the company said.On Stocktwits, retail sentiment around IDEXX fell from ‘extremely bullish’ to ‘bullish’ territory over the past 24 hours while message volume jumped from ‘extremely low’ to ‘high’ levels.<figure class="image"><img style="aspect-ratio:631/69;" src="https://news.stocktwits-cdn.com/Screenshot_2025_05_01_at_1_42_40_PM_png_db37931bed.webp" alt="IDXX's Sentiment Meter and Message Volume as of 1:40 p.m. ET on May 1, 2025 | Source: Stocktwits" width="631" height="69"><figcaption>IDXX's Sentiment Meter and Message Volume as of 1:40 p.m. ET on May 1, 2025 | Source: Stocktwits</figcaption></figure> <a href="https://stocktwits.com/symbol/IDXX">IDXX stock</a> is up by over 15% so far this year and by nearly 1% over the past 12 months.Also See: <a href="https://stocktwits.com/news-articles/markets/equity/byd-reports-21-percent-jump-in-ev-sales-in-april/chLvX7XRb0R">BYD Reports 21% Jump In April EV Sales: Retail’s Optimistic</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Rising stock market chart on a trading board background.

The company has adjusted its full-year revenue guidance to $4.1 billion to $4.21 billion, reflecting the benefits of foreign exchange impacts, up from its previous estimate of $4.06 billion to $4.17 billion.

Idexx Laboratories Inc

Vanguard S&P 500 ETF

Vanguard Total Stock Market ETF

Hold rates steady

Cut 25 bps

Hike 25 bps

Fed decision day is here - Kevin Warsh chairs his first FOMC meeting with markets pricing a hold at 3.50%-3.75% but watching for a hawkish shift. Vote on what you expect to be decided today, then drop your prediction for the first rate cut or hike in the comments.

What do you expect the Fed to decide at its FOMC meeting today? 
 
Drop a comment with when you expect the first cut/hike to be.

Current Price	$551.21
Prev Close	$575.98
Open	$583.75
Dividend Yield	0.00%
50-Day Moving Average	$534.27
Beta	0.95
Avg. Volume	508,656.50
PE Ratio	38.74

52-Week High	$769.98
52-Week Low	$500.61
Market Capitalization	$43.42B
EPS (Annual)	$13.08
Price to Book	26.96
Revenue Per Employee	$391,245.64

Feed

News

Sentiment

Earnings

Fundamentals

Info

IDXX Fundamentals